Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating R&D spend for Penumbra’s Lightning Flash thrombectomy platform or tracking how stroke-care sales trend across 100+ countries can feel like navigating a catheter through tight anatomy. The company’s disclosures span hundreds of pages, and the detail investors need—product line revenue, pipeline milestones, or 510(k) updates—often hides deep inside footnotes.
Stock Titan turns that complexity into clarity. Our AI reads every Penumbra annual report 10-K simplified, each Penumbra quarterly earnings report 10-Q filing, and even the swift Penumbra 8-K material events explained, then extracts what matters. Need Penumbra insider trading Form 4 transactions before market open? We send alerts the moment a Penumbra Form 4 insider transactions real-time hits EDGAR. Wonder how directors are paid? The Penumbra proxy statement executive compensation is summarized in plain English. For fast answers, just ask “understanding Penumbra SEC documents with AI” or “Penumbra earnings report filing analysis” and jump straight to the insight.
What you’ll uncover here:
- Device segment revenue shifts across neurovascular and peripheral vascular markets
- Regulatory milestones that could accelerate sales growth
- Penumbra executive stock transactions Form 4 patterns around product launches
Whether you’re screening for valuation catalysts or monitoring compliance risk, this page delivers every filing—10-K, 10-Q, 8-K, S-8, and more—with real-time updates and AI-powered summaries that explain filing meanings in simple terms. No more PDF scavenging; the critical data on Penumbra SEC filings explained simply is already parsed and ready for decision-making.
Penumbra (PEN) filed a Form 144 notice for a planned secondary sale of common stock. A shareholder intends to sell 30,000 shares of Penumbra common stock through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of
Penumbra Inc. reported insider equity activity by its Chief Financial Officer, Maggie Yuen. On November 17, 2025, she was granted 3,580 restricted stock units (RSUs) under Penumbra's Amended and Restated 2014 Equity Incentive Plan. One quarter of these RSUs will vest each year on November 15, beginning in 2026, subject to her continued service.
On November 15, 2025, Penumbra withheld 364 shares of common stock and separately 327 shares to cover tax withholding obligations related to vesting RSUs. After these transactions and the new grant, Yuen beneficially owned 16,556 shares of Penumbra common stock directly.
Penumbra, Inc. (PEN) reported an insider equity transaction involving its President, Shruthi Narayan. On 11/15/2025, the company withheld 358 shares of common stock at a price of $280.07 per share. These shares were withheld to cover tax obligations that arose when previously granted restricted stock units vested.
After this tax withholding transaction, Narayan beneficially owned 26,603 shares of Penumbra common stock in direct ownership, and a portion of these shares remains subject to vesting. The filing is a routine disclosure of equity compensation and related tax withholding rather than an open-market purchase or sale.
Penumbra, Inc. (PEN)November 15, 2025, the company withheld 346 and 506 shares of common stock at $280.07 per share to cover tax obligations tied to vesting restricted stock units (RSUs). On November 17, 2025, Shiu received a grant of 3,580 RSUs under Penumbra's Amended and Restated 2014 Equity Incentive Plan, which will vest in four equal annual installments beginning on November 15, 2026, subject to continued service. After these transactions, Shiu beneficially owned 35,565 Penumbra shares directly, including shares subject to vesting, plus 300 shares held indirectly through a spouse's IRA.
Penumbra, Inc. executive Johanna Roberts, EVP, General Counsel & Secretary, reported equity transactions in the company’s common stock. On November 15, 2025, a total of 701 shares of common stock were withheld by Penumbra to cover tax obligations tied to vesting restricted stock units (RSUs), reducing her directly held shares to 62,956. On November 17, 2025, she received a grant of 3,580 RSUs under Penumbra’s Amended and Restated 2014 Equity Incentive Plan at a price of $0, bringing her directly beneficially owned common stock to 66,536 shares, a portion of which remains subject to vesting. One quarter of the new RSU grant is scheduled to vest annually beginning on November 15, 2026, conditioned on continued service.
Penumbra (PEN) reported insider transactions by its EVP, General Counsel & Secretary. On 11/10/2025, the officer sold small blocks of common stock in multiple open‑market trades executed under a Rule 10b5-1 trading plan. Weighted average sale prices by lot ranged from $263.58 to $269.56. Following these sales, the reporting person beneficially owned 63,657 shares directly. A portion of these shares is subject to vesting.
Penumbra (PEN) disclosed an insider transaction by Director Harpreet Grewal. On 11/04/2025, the reporting person sold 186 shares of common stock at a price of $227.58 per share, coded as “S.” The filing notes the sale was made under a Rule 10b5-1 trading plan. Following the transaction, 8,516 shares are beneficially owned in direct form. The filing also states that a portion of these shares is subject to vesting.
Penumbra (PEN) reported stronger Q3 results with revenue of $354.7 million, up from $301.0 million a year ago, and net income of $45.9 million versus $29.5 million. Operating income rose to $48.8 million from $35.4 million as gross profit increased to $240.4 million. Thrombectomy contributed $236.4 million and Embolization & Access $118.3 million. U.S. sales were $275.0 million and international $79.7 million.
For the first nine months, revenue reached $1,018.3 million (from $879.1 million) and net income was $130.3 million compared to a loss of $19.7 million last year. Cash and cash equivalents were $321.0 million, with $149.3 million in marketable investments, and operating cash flow of $152.2 million year‑to‑date. The company is building a ~330,000 sq. ft. Costa Rica facility, expecting about $35 million in project costs plus $23 million of improvements; $28.3 million was paid through Q3. The board extended the remaining $100.0 million share repurchase authorization to December 31, 2025. The prior immersive healthcare wind‑down carried no new charges in 2025.
Penumbra, Inc. furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The information was furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated into other filings unless specifically referenced. The report was signed by CFO Maggie Yuen on November 5, 2025.
Penumbra, Inc. (PEN): Notice of proposed sale under Rule 144. A holder filed to sell 186 shares of Penumbra common stock through Fidelity Brokerage Services LLC, with an aggregate market value $42,329.88. The shares are listed on the NYSE, with an approximate sale date of 11/04/2025.
The securities to be sold were acquired on 09/30/2025 as a stock award from Penumbra in the amount of 186 shares. As context, Penumbra reported 38,999,129 shares outstanding. The filer also reported sales in the prior three months: 186 shares on 09/02/2025 for $50,627.34 and 186 shares on 10/02/2025 for $46,241.46.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
